{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:33:56Z","timestamp":1786991636577,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":392,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Interventions"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jcin.2022.08.009","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T16:49:55Z","timestamp":1666802995000},"page":"2239-2249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["P2Y12 Inhibitor or Aspirin Following Dual\u00a0Antiplatelet Therapy After Percutaneous Coronary Intervention"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5552-6382","authenticated-orcid":false,"given":"Giuseppe","family":"And\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Azzurra","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Pistelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Francaviglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piera","family":"Capranzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcin.2022.08.009_bib1","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Lawton","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2022.08.009_bib2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1161\/CIRCULATIONAHA.120.046308","article-title":"Dual antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents: a systematic review and network meta-analysis","volume":"142","author":"Khan","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2022.08.009_bib3","doi-asserted-by":"crossref","first-page":"n1332","DOI":"10.1136\/bmj.n1332","article-title":"P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials","volume":"373","author":"Valgimigli","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jcin.2022.08.009_bib4","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2022.08.009_bib5","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jcin.2022.08.009_bib6","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.4244\/EIJ-D-21-00870","article-title":"Ticagrelor monotherapy versus aspirin monotherapy at 12\u00a0months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial","volume":"18","author":"Ono","year":"2022","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2022.08.009_bib7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jacc.2021.10.028","article-title":"Magnetically controlled capsule endoscopy for assessment of antiplatelet therapy-induced gastrointestinal injury","volume":"79","author":"Han","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2022.08.009_bib8","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcin.2022.08.009_bib9","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jcin.2022.08.009_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jclinepi.2019.03.007","article-title":"The number needed to treat in pairwise and network meta-analysis and its graphical representation","volume":"111","author":"Veroniki","year":"2019","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jcin.2022.08.009_bib11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jclinepi.2016.02.016","article-title":"The rank-heat plot is a novel way to present the results from a network meta-analysis including multiple outcomes","volume":"76","author":"Veroniki","year":"2016","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jcin.2022.08.009_bib12","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A\u00a0new strategy for discontinuation of dual antiplatelet therapy: the RESET trial (Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Endeavor Zotarolimus-Eluting Stent Implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2022.08.009_bib13","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2022.08.009_bib14","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial","volume":"64","author":"Colombo","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2022.08.009_bib15","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial","volume":"65","author":"Gilard","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2022.08.009_bib16","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.003145","article-title":"Six versus 12\u00a0months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial","volume":"9","author":"Han","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2022.08.009_bib17","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jcin.2016.04.036","article-title":"6-Month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial","volume":"9","author":"Hong","year":"2016","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2022.08.009_bib18","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jcin.2017.04.019","article-title":"Dual antiplatelet therapy for 6 versus 18\u00a0months after biodegradable polymer drug-eluting stent implantation","volume":"10","author":"Nakamura","year":"2017","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2022.08.009_bib19","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-Month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2022.08.009_bib20","doi-asserted-by":"crossref","first-page":"k3793","DOI":"10.1136\/bmj.k3793","article-title":"Six months versus 12\u00a0months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial","volume":"363","author":"Kedhi","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jcin.2022.08.009_bib21","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.4244\/EIJ-D-17-00792","article-title":"Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C randomised clinical trial and OCT substudy","volume":"13","author":"Lee","year":"2018","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2022.08.009_bib22","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.4244\/EIJ-D-19-00539","article-title":"Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)","volume":"15","author":"De Luca","year":"2019","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2022.08.009_bib23","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.jcin.2021.06.003","article-title":"1-Month dual-antiplatelet therapy followed by aspirin monotherapy after polymer-free drug-coated stent implantation: one-month DAPT trial","volume":"14","author":"Hong","year":"2021","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2022.08.009_bib24","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2022.08.009_bib25","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2022.08.009_bib26","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2022.08.009_bib27","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2022.08.009_bib28","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/j.jacc.2019.08.1038","article-title":"Ticagrelor alone versus dual antiplatelet therapy from 1\u00a0month after drug-eluting coronary stenting","volume":"74","author":"Franzone","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2022.08.009_bib29","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.002816","article-title":"Clopidogrel versus aspirin as an antiplatelet monotherapy after 12-month dual-antiplatelet therapy in the era of drug-eluting stents","volume":"9","author":"Park","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2022.08.009_bib30","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4070\/kcj.2019.0166","article-title":"Clopidogrel versus aspirin after dual antiplatelet therapy in acute myocardial infarction patients undergoing drug-eluting stenting","volume":"50","author":"Sim","year":"2020","journal-title":"Korean Circ J"},{"key":"10.1016\/j.jcin.2022.08.009_bib31","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/S0140-6736(20)30315-9","article-title":"Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis","volume":"395","author":"Chiarito","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2022.08.009_bib32","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jacc.2018.11.053","article-title":"PCI and CABG for treating stable coronary artery disease: JACC review topic of the week","volume":"73","author":"Doenst","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2022.08.009_bib33","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.113.006518","article-title":"Trends in cause of death after percutaneous coronary intervention","volume":"129","author":"Spoon","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2022.08.009_bib34","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4244\/EIJ-D-20-00145","article-title":"Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes","volume":"16","author":"Franzone","year":"2020","journal-title":"EuroIntervention"}],"container-title":["JACC: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879822015527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879822015527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:16:49Z","timestamp":1761848209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936879822015527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":34,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1936879822015527"],"URL":"https:\/\/doi.org\/10.1016\/j.jcin.2022.08.009","relation":{},"ISSN":["1936-8798"],"issn-type":[{"value":"1936-8798","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"P2Y12 Inhibitor or Aspirin Following Dual\u00a0Antiplatelet Therapy After Percutaneous Coronary Intervention","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcin.2022.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}